BioLineRx Ltd. (BLRX)
BLRXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.52
-0.0600 (-3.80%) today
Regular session, Nov 10, 1:46 PM ET
- Market cap
- $7.57m
- P/E
- –
- EPS, last 4 quarters
- $-1.69
- Dividend yield
- –
- Day range
- $1.45 to $1.75
- 52-week range
- $1.58 to $3.95
- Average volume
- 18.6k
- Previous close
- $1.58
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $26.00, +1610.5% from here
Earnings
next estimate $-0.3800Next report Nov 23, 2026
Sep 2025
+46.3%
Dec 2025
+32.0%
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Dec 2009 |
|---|---|
| Revenue | $16.87m |
| Gross profit | $10.90m |
| Operating income | -$16.71m |
| Net income | -$16.24m |
News
8 latest- BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026Fintel · Oct 23, 2026
- BioLineRx And Hemispherian To Present GLIX1 Data At EANO 2026; Stock Up RTTNews · Sep 10, 2026
- Lifeward Names Josh Hexter Interim CEO, Rami Aviram As CFO RTTNews · Aug 31, 2026
- BioLineRx (BLRX) Q1 2026 Earnings TranscriptThe Motley Fool · May 29, 2026
- 3 Stocks Getting Rare Double Upgrades From AnalystsMarketBeat · Jun 6, 2025
- Jones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX)Fintel · May 30, 2025
- BioLineRx Reports Promising Motixafortide Combo Data In PDAC Ahead Of ASCO 2025 RTTNews · May 30, 2025
- Pre-Market Earnings Report for March 31, 2025 : PVLA, LIEN, WPRT, FTCI, PRPH, BLRX, WKHS, BCLI, LMFA, IMCCNASDAQ.com · Mar 28, 2025
The company
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial was initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS. The Company's first approved product, APHEXDA (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Auspex Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- biolinerx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.